Chemotherapy Plus Gefitinib Versus Gefitinib Alone as First-line Treatment for Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

NCT02951637 Phase 2 UNKNOWN

The purpose of this study is to compare chemotherapy and gefitinib in combination with gefitinib alone as first-line therapy for adenocarcinoma, in terms of efficacy and safety.

Details

Lead sponsor	Shanghai Chest Hospital
Phase	Phase 2
Status	UNKNOWN
Enrolment	300
Start date	2016-12
Completion	2019-12

Conditions

• Lung Adenocarcinoma

Interventions

• Pemetrexed plus carboplatin combined with gefitinib
• Gefitinib

Primary outcomes

• Progression-free survival (PFS) — 16 months